종양 전사체학 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 종양 유형별, 기술별, 제품 유형별, 용도별, 최종사용자별, 지역별, 경쟁별(2020-2030년)

The Global Tumor Transcriptomics Market, valued at USD 6.02 Billion in 2024, is projected to experience a CAGR of 6.34% to reach USD 8.71 Billion by 2030. Tumor transcriptomics involves the comprehensive analysis of ribonucleic acid transcripts within cancer cells, providing essential insights into gene expression patterns, disease classification, and progression. This market's expansion is primarily supported by the increasing global prevalence of various cancer types and continuous advancements in genomic sequencing technologies.

Key Market Drivers

The escalating global incidence of cancer serves as a primary catalyst for the expansion of the tumor transcriptomics market. As cancer rates continue to rise across diverse populations, there is a sustained demand for sophisticated diagnostic and prognostic tools capable of unraveling complex molecular signatures of various tumor types. Tumor transcriptomics offers unparalleled insights into gene expression patterns and disease progression, crucial for effective clinical management and treatment stratification. According to the International Agency for Research on Cancer, in February 2024, "Global cancer burden growing, amidst mounting need for services" article, in 2022 there were an estimated 20 million new cancer cases worldwide, highlighting the extensive patient population requiring advanced molecular profiling. This pervasive disease burden necessitates continuous innovation in transcriptomic analysis to provide actionable information for clinicians.

Key Market Challenges

The scarcity of professionals possessing specialized expertise in both molecular biology and the bioinformatics required for complex analysis represents a significant impediment to the Global Tumor Transcriptomics Market's expansion. These specialists are critical for interpreting the vast and intricate transcriptomic datasets, which are fundamental for precise disease classification, understanding progression, and guiding therapeutic strategies. Without sufficient qualified personnel, the advanced genomic sequencing technologies, despite continuous advancements, cannot be fully leveraged.

Key Market Trends

The emergence of spatial tumor transcriptomics for tissue analysis is significantly influencing the market by enabling researchers to precisely map gene expression within the architectural context of a tumor, providing insights into cellular interactions and disease microenvironments that bulk sequencing cannot. This technology is becoming crucial for understanding tumor heterogeneity and identifying novel biomarkers for targeted therapies. For example, Vizgen, a company at the forefront of this technology, announced the first global shipments of its MERSCOPE Ultra Platform in September 2024, delivering enhanced capabilities to leading research institutions worldwide to accelerate discoveries in spatial genomics. This advancement, which triples the imaging area of its predecessor to 3.0 cm2 on a single slide and offers faster imaging speeds, underscores the growing demand for high-resolution spatial multiomic analysis systems to propel foundational and clinical research.

Key Market Players

• Thermo Fischer Scientific, Inc.
• Caris Life Sciences.
• Illumina, Inc.
• NanoString Technologies, Inc.
• 10x Genomics, Inc.
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche AG
• Standard BioTools Inc.
• Pacific Biosciences of California, Inc.

Report Scope:

In this report, the Global Tumor Transcriptomics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Tumor Transcriptomics Market, By Tumor Type:

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Melanoma
• Others

Tumor Transcriptomics Market, By Technology:

• Microarray
• Real-Time Quantitative
• Polymerase Chain Reaction (Q-PCR)
• Others

Tumor Transcriptomics Market, By Product:

• Consumables
• Instrument
• Software & Services

Tumor Transcriptomics Market, By Application:

• Diagnostics and Disease Profiling
• Drug Discovery
• Others

Tumor Transcriptomics Market, By End User:

• Biotechnology & Pharmaceutical Companies
• Research & Academic Institutions
• Others

Tumor Transcriptomics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Tumor Transcriptomics Market.

Available Customizations:

Global Tumor Transcriptomics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Tumor Transcriptomics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Tumor Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Others)
  • 5.2.2. By Technology (Microarray, Real-Time Quantitative, Polymerase Chain Reaction (Q-PCR), Others)
  • 5.2.3. By Product (Consumables, Instrument, Software & Services)
  • 5.2.4. By Application (Diagnostics and Disease Profiling, Drug Discovery, Others)
  • 5.2.5. By End User (Biotechnology & Pharmaceutical Companies, Research & Academic Institutions, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2024)
• 5.3. Market Map

6. North America Tumor Transcriptomics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Tumor Type
  • 6.2.2. By Technology
  • 6.2.3. By Product
  • 6.2.4. By Application
  • 6.2.5. By End User
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Tumor Transcriptomics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Tumor Type
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Product
      • 6.3.1.2.4. By Application
      • 6.3.1.2.5. By End User
  • 6.3.2. Canada Tumor Transcriptomics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Tumor Type
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Product
      • 6.3.2.2.4. By Application
      • 6.3.2.2.5. By End User
  • 6.3.3. Mexico Tumor Transcriptomics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Tumor Type
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Product
      • 6.3.3.2.4. By Application
      • 6.3.3.2.5. By End User

7. Europe Tumor Transcriptomics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Tumor Type
  • 7.2.2. By Technology
  • 7.2.3. By Product
  • 7.2.4. By Application
  • 7.2.5. By End User
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Tumor Transcriptomics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Tumor Type
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Product
      • 7.3.1.2.4. By Application
      • 7.3.1.2.5. By End User
  • 7.3.2. France Tumor Transcriptomics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Tumor Type
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Product
      • 7.3.2.2.4. By Application
      • 7.3.2.2.5. By End User
  • 7.3.3. United Kingdom Tumor Transcriptomics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Tumor Type
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Product
      • 7.3.3.2.4. By Application
      • 7.3.3.2.5. By End User
  • 7.3.4. Italy Tumor Transcriptomics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Tumor Type
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Product
      • 7.3.4.2.4. By Application
      • 7.3.4.2.5. By End User
  • 7.3.5. Spain Tumor Transcriptomics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Tumor Type
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Product
      • 7.3.5.2.4. By Application
      • 7.3.5.2.5. By End User

8. Asia Pacific Tumor Transcriptomics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Tumor Type
  • 8.2.2. By Technology
  • 8.2.3. By Product
  • 8.2.4. By Application
  • 8.2.5. By End User
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Tumor Transcriptomics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Tumor Type
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Product
      • 8.3.1.2.4. By Application
      • 8.3.1.2.5. By End User
  • 8.3.2. India Tumor Transcriptomics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Tumor Type
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Product
      • 8.3.2.2.4. By Application
      • 8.3.2.2.5. By End User
  • 8.3.3. Japan Tumor Transcriptomics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Tumor Type
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Product
      • 8.3.3.2.4. By Application
      • 8.3.3.2.5. By End User
  • 8.3.4. South Korea Tumor Transcriptomics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Tumor Type
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Product
      • 8.3.4.2.4. By Application
      • 8.3.4.2.5. By End User
  • 8.3.5. Australia Tumor Transcriptomics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Tumor Type
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Product
      • 8.3.5.2.4. By Application
      • 8.3.5.2.5. By End User

9. Middle East & Africa Tumor Transcriptomics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Tumor Type
  • 9.2.2. By Technology
  • 9.2.3. By Product
  • 9.2.4. By Application
  • 9.2.5. By End User
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Tumor Transcriptomics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Tumor Type
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Product
      • 9.3.1.2.4. By Application
      • 9.3.1.2.5. By End User
  • 9.3.2. UAE Tumor Transcriptomics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Tumor Type
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Product
      • 9.3.2.2.4. By Application
      • 9.3.2.2.5. By End User
  • 9.3.3. South Africa Tumor Transcriptomics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Tumor Type
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Product
      • 9.3.3.2.4. By Application
      • 9.3.3.2.5. By End User

10. South America Tumor Transcriptomics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Tumor Type
  • 10.2.2. By Technology
  • 10.2.3. By Product
  • 10.2.4. By Application
  • 10.2.5. By End User
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Tumor Transcriptomics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Tumor Type
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Product
      • 10.3.1.2.4. By Application
      • 10.3.1.2.5. By End User
  • 10.3.2. Colombia Tumor Transcriptomics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Tumor Type
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Product
      • 10.3.2.2.4. By Application
      • 10.3.2.2.5. By End User
  • 10.3.3. Argentina Tumor Transcriptomics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Tumor Type
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Product
      • 10.3.3.2.4. By Application
      • 10.3.3.2.5. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Tumor Transcriptomics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fischer Scientific, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Caris Life Sciences.
• 15.3. Illumina, Inc.
• 15.4. NanoString Technologies, Inc.
• 15.5. 10x Genomics, Inc.
• 15.6. Agilent Technologies, Inc.
• 15.7. Bio-Rad Laboratories, Inc.
• 15.8. F. Hoffmann-La Roche AG
• 15.9. Standard BioTools Inc.
• 15.10. Pacific Biosciences of California, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer